What is the official website of ExecuPharm ?

The official website of ExecuPharm is https://http://www.execupharm.com.

What is ExecuPharm's cybersecurity risk score?

ExecuPharm has an AI-generated cybersecurity risk score of 718 out of 1000, indicating a Moderate security posture according to Rankiteo's assessment.

How many security incidents has ExecuPharm experienced?

According to Rankiteo, ExecuPharm currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has ExecuPharm been affected by any supply chain cyber incidents ?

According to Rankiteo, ExecuPharm has been affected by a supply chain cyber incident involving Oracle, with the incident ID ORAPAR1766015901.

Does ExecuPharm have SOC 2 Type 1 certification ?

According to Rankiteo, ExecuPharm is not certified under SOC 2 Type 1.

Does ExecuPharm have SOC 2 Type 2 certification ?

According to Rankiteo, ExecuPharm does not hold a SOC 2 Type 2 certification.

Does ExecuPharm comply with GDPR ?

According to Rankiteo, ExecuPharm is not listed as GDPR compliant.

Does ExecuPharm have PCI DSS certification ?

According to Rankiteo, ExecuPharm does not currently maintain PCI DSS compliance.

Does ExecuPharm comply with HIPAA ?

According to Rankiteo, ExecuPharm is not compliant with HIPAA regulations.

Does ExecuPharm have ISO 27001 certification ?

According to Rankiteo,ExecuPharm is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does ExecuPharm operate in ?

ExecuPharm operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does ExecuPharm have ?

ExecuPharm employs approximately 293 people worldwide.

Does ExecuPharm own any subsidiaries ?

ExecuPharm presently has no subsidiaries across any sectors.

How many LinkedIn followers does ExecuPharm have ?

ExecuPharm's official LinkedIn profile has approximately 42,506 followers.

What is the NAICS classification code for ExecuPharm ?

ExecuPharm is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does ExecuPharm have a Crunchbase profile ?

No, ExecuPharm does not have a profile on Crunchbase.

Does ExecuPharm have a LinkedIn profile ?

Yes, ExecuPharm maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/parexelfsp.

How many cybersecurity incidents has ExecuPharm experienced ?

As of June 15, 2026, Rankiteo reports that ExecuPharm has experienced 2 cybersecurity incidents.

How many peer or competitor companies does ExecuPharm have ?

ExecuPharm has an estimated 5,686 peer or competitor companies worldwide.

What types of cybersecurity incidents has ExecuPharm faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Vulnerability and Ransomware.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

ExecuPharm

Boost Score +25 with badge (5 left)

718

/1000

Moderate

743

/1000

Moderate

ExecuPharm Vendor Cyber Rating & Cyber Score

execupharm.com

Add Your Compliance Badge

ExecuPharm is the North American clinical operations business of Parexel FSP. 10+ years of Experience Meeting Client Needs 10,000+ Global Clinical Operational Specialists In Network 80% of Recruiting Staff with >15 Years of Experience Talent Acquisition, Deployment Rates, and Employee Retention above 90% Management Staff with Tangible Industry Experience Greater Than 95% Repeat Business Average Turnaround Time of 14 Days To Deploy Project Team Resources

ExecuPharm A.I CyberSecurity Scoring

Scoring History

ExecuPharm

ExecuPharm CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Parexel

Vulnerability

10/2025

Oracle

ORAPAR176601590...

ExecuPharm

Ransomware

3/2020

EXEPAR176974207...

Loading…

A.I.

ExecuPharm Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for ExecuPharm

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for ExecuPharm in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for ExecuPharm in 2026.

Incident Types ExecuPharm vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for ExecuPharm in 2026.

Incident History - ExecuPharm (X = Date, Y = Severity)

Loading…

SUBSIDIARY

ExecuPharm Subsidiaries

ExecuPharm

Pharmaceutical Manufacturing

Website: https://http://www.execupharm.com

Company Size: 293

ParexelPharmaceutical Manufacturing

Loading…

ExecuPharm Similar Companies

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Loading…

NEWS

ExecuPharm CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

November 08, 2024 03:28 AM

Cybercriminals Leak ExecuPharm Internal Documents After Ransomware Attack

A successful ransomware attack was deployed on March 13 against ExecuPharm, a subsidiary of the US Biopharmaceutical giant Parexel.

Read Article

August 16, 2024 07:00 AM

Understanding healthcare data breach lawsuit trends

Lawsuits often follow a healthcare data breach, but understanding what drives litigation trends can help healthcare organizations prepare.

Read Article

September 20, 2022 07:00 AM

Data breach, but no identity theft: Can employee still sue?

An important new ruling says an employee can sue her employer even though a data breach did not lead to identity theft or fraud.

Read Article

April 29, 2020 07:00 AM

ExecuPharm, Subsidiary of US Biopharmaceutical Giant Parexel, Hit by Ransomware Attack

ExecuPharm, a subsidiary of the U.S. Biopharmaceutical giant Parexel, has been hit by a ransomware attack according to a recent announcement...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-12191

SUMMARY

A vulnerability was found in Comma AI Openpilot 0.11. This issue affects the function pickle.load/pickle.loads of the file selfdrive/modeld/modeld.py of the component Pickle Module. The manipulation results in deserialization. The attack is only possible with local access. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-14

Updated

Date2026-06-14

RISK INFORMATION (Score: 7.8)

cvss2

Base Score: 6.8

Complexity: LOW

AV:L/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

1.8

REFERENCES

CVE-2026-12190

SUMMARY

A vulnerability has been found in Genspark AI Workspace App 2.8.4 on Android. This vulnerability affects unknown code of the component ai.mainfunc.genspark. The manipulation leads to improper authorization in handler for custom url scheme. The attack can only be performed from a local environment. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-14

Updated

Date2026-06-14

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 4.3

Complexity: LOW

AV:L/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 4.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

1.8

REFERENCES

CVE-2026-12189

SUMMARY

A flaw has been found in Moovit Bus & Public Transit App 1.18 on Android. This affects an unknown part of the component com.tranzmate. Executing a manipulation can lead to improper authorization in handler for custom url scheme. The attack can only be executed locally. The exploit has been published and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-14

Updated

Date2026-06-14

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 4.3

Complexity: LOW

AV:L/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 1.9

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

1.8

REFERENCES

CVE-2026-12188

SUMMARY

A vulnerability was detected in Grit42 Grit up to 0.11.0. Affected by this issue is some unknown functionality of the file modules/core/backend/app/controllers/concerns/grit/core/grit_entity_controller.rb of the component GritEntityController. Performing a manipulation results in sql injection. The attack may be initiated remotely. The exploit is now public and may be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-06-14

Updated

Date2026-06-14

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-12187

SUMMARY

A security vulnerability has been detected in GL.iNet GL-MT3000 up to 4.4.5. Affected by this vulnerability is an unknown functionality of the file /usr/bin/one_click_upgrade of the component Online Firmware Upgrade Handler. Such manipulation leads to command injection. The attack can be launched remotely. The exploit has been disclosed publicly and may be used. Upgrading to version 4.7 addresses this issue. Upgrading the affected component is advised. The vendor was contacted early, responded in a very professional manner and quickly released a fixed version of the affected product.

Published

Date2026-06-14

Updated

Date2026-06-14

RISK INFORMATION (Score: 8.8)

cvss2

Base Score: 9.0

Complexity: LOW

AV:N/AC:L/Au:S/C:C/I:C/A:C

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 7.4

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…